Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AEYE Health

Request full access

AEYE Health is a digital health company that aims to enable automated, AI-based retinal screening

Tel Aviv-Yafo, IsraelFounded 2016Health Tech & Medtech

About AEYE Health

AEYE Health, a digital health firm established in 2018, operates from New York and Tel Aviv. The company was co-founded by Zack Dvey-Aharon, PhD, and Danny Margalit. Dvey-Aharon, the CEO, is a serial entrepreneur with a PhD in machine learning from Tel Aviv University and a background in the Israeli Defense Forces' intelligence corps. His interest in the field began at a young age and was solidified during his PhD research, where he recognized the eye's potential as a mirror to the body's health. Margalit, the COO, previously co-founded Aladdin, which had a NASDAQ IPO.

The company's core business revolves around providing fully autonomous, AI-powered diagnostic screening solutions for retinal imaging. This technology is designed to be integrated into primary care settings, endocrinology clinics, pharmacies, and even home-care environments, making retinal screenings more accessible and affordable. By enabling non-specialists to conduct these screenings, AEYE Health aims to increase adherence to annual eye exams, particularly for the millions of diabetic patients at risk of diabetic retinopathy, a leading cause of blindness in working-age adults. The business model is supported by a CPT code for autonomous AI-based screening, which allows healthcare providers to be reimbursed for the service.

AEYE Health's flagship product is the AEYE-DS, an AI-based system that analyzes retinal images to detect various conditions. In November 2022, the company received its first FDA 510(k) clearance to market the system for detecting more-than-mild diabetic retinopathy. A significant milestone occurred in April 2024, when AEYE Health secured a second FDA clearance for its technology to be used with a portable, handheld camera, the Optomed Aurora. This clearance established the AEYE-DS as the first fully autonomous AI solution cleared for use with both portable and tabletop devices. The system delivers diagnostic results in under a minute, using just a single image per eye, and rarely requires pupil dilation, enhancing its usability in point-of-care settings. Clinical studies demonstrated high sensitivity and specificity for the technology. Beyond diabetic retinopathy, the company is developing its platform to screen for other conditions like glaucoma, AMD, hypertension, and cardiovascular risk.

Source: Dealroom company data

At a glance

Status
Operational
Employees
39
Open positions
None listed
Dealroom signal
81.8/100
Industry
Health
Sub-industry
Medical Devices, Health Platform
Sector
Data Analytics, Predictive Analytics, Screening, Non-Invasive medical devices and treatments, Clinical Decision Support, Tech for Medical Professionals
Technology
Artificial Intelligence, Big Data, Deep Tech, Machine Learning
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2022 $10M $40M Undisclosed —
SEEDEquity / VC Jan 2022 $10M $40M Undisclosed ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

AEYE Health website traffic

Latest recorded traffic for AEYE Health is 4.7K monthly website visits, down 20.3% over the last three months. AEYE Health's team grew 5.4% over the past year.

Latest monthly visits4.7K 3-month web change-20.3% 1-year team growth+5.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AEYE Health in the Tel Aviv-Yafo ecosystem

Live from Dealroom

The AEYE Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

  • Sky Ventures Group
  • Falcon Ventures
  • Club 100 Plus
  • BioLight Israeli Life Sciences Investments Ltd
  • Sean Ianchulev
  • 100 Club
  • SK

Other known investors2 additional known investors

Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇮🇱 Israel50%
🇺🇸 United States43.8%
🇳🇿 New Zealand3.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AEYE Health on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AEYE Health’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.